Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
5
Novel Nano-emulsion Immuno-suppressive Adjuvant for Allergy Vaccines
Award last edited on: 8/18/20
Sponsored Program
SBIR
Awarding Agency
NIH
Total Award Amount
$600,000
Award Phase
1
Solicitation Topic Code
NIAID
Principal Investigator
Michael S Vajdy
Company Information
EpitoGenesis Inc
933 Hartford Turnpike
Vernon, CT 06066
(860) 990-5908
info@epitogenesis.com
www.epitogenesis.com
Location:
Single
Congr. District:
02
County:
Tolland
Phase I
Contract Number:
75N93019C00039
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2019
Phase I Amount
$600,000
Bronchial asthma is a chronic respiratory disease that can be lethal Asthma is a global health problem According to the CDC in USA there are currently million asthma sufferers and this number is increasing Half of the asthma patients have at least one hospitalization per year with an annual medical cost of $B Traditionally asthma is treated during flare ups with prescribed inhaled corticosteriods In recent years various forms of immunotherapies such as sublingual treatment with large doses of allergens have been used to alleviate symptomsIn modern vaccine adjuvant research the concept of allergen specific therapeutic allergy vaccines are introduced We previously developed an immune enhancing vaccine adjuvant formulation based on the synergy between vitamins A and E and a flavonoid as an oil in water emulsion NIDS and obtained safety and protective efficacy as well as long term shelf stability results for rather result in antigen specific suppression of serum antibody responses following intra muscular vaccinations This together with the fact that the components used can be anti inflammatory lead us to design a therapeutic allergy vaccine adjuvant platform as proposed herein
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.